194 related articles for article (PubMed ID: 32014997)
1. Inactivation of mesotrypsin by chymotrypsin C prevents trypsin inhibitor degradation.
Toldi V; Szabó A; Sahin-Tóth M
J Biol Chem; 2020 Mar; 295(11):3447-3455. PubMed ID: 32014997
[TBL] [Abstract][Full Text] [Related]
2. Mesotrypsin Signature Mutation in a Chymotrypsin C (CTRC) Variant Associated with Chronic Pancreatitis.
Szabó A; Ludwig M; Hegyi E; Szépeová R; Witt H; Sahin-Tóth M
J Biol Chem; 2015 Jul; 290(28):17282-92. PubMed ID: 26013824
[TBL] [Abstract][Full Text] [Related]
3. Human mesotrypsin is a unique digestive protease specialized for the degradation of trypsin inhibitors.
Szmola R; Kukor Z; Sahin-Tóth M
J Biol Chem; 2003 Dec; 278(49):48580-9. PubMed ID: 14507909
[TBL] [Abstract][Full Text] [Related]
4. Mouse model suggests limited role for human mesotrypsin in pancreatitis.
Mosztbacher D; Sahin-Tóth M
Pancreatology; 2021 Mar; 21(2):342-352. PubMed ID: 33526384
[TBL] [Abstract][Full Text] [Related]
5. Autoactivation of mouse trypsinogens is regulated by chymotrypsin C via cleavage of the autolysis loop.
Németh BC; Wartmann T; Halangk W; Sahin-Tóth M
J Biol Chem; 2013 Aug; 288(33):24049-62. PubMed ID: 23814066
[TBL] [Abstract][Full Text] [Related]
6. Tighter Control by Chymotrypsin C (CTRC) Explains Lack of Association between Human Anionic Trypsinogen and Hereditary Pancreatitis.
Jancsó Z; Sahin-Tóth M
J Biol Chem; 2016 Jun; 291(25):12897-905. PubMed ID: 27129265
[TBL] [Abstract][Full Text] [Related]
7. Mesotrypsin Has Evolved Four Unique Residues to Cleave Trypsin Inhibitors as Substrates.
Alloy AP; Kayode O; Wang R; Hockla A; Soares AS; Radisky ES
J Biol Chem; 2015 Aug; 290(35):21523-35. PubMed ID: 26175157
[TBL] [Abstract][Full Text] [Related]
8. Increased activation of hereditary pancreatitis-associated human cationic trypsinogen mutants in presence of chymotrypsin C.
Szabó A; Sahin-Tóth M
J Biol Chem; 2012 Jun; 287(24):20701-10. PubMed ID: 22539344
[TBL] [Abstract][Full Text] [Related]
9. Human mesotrypsin defies natural trypsin inhibitors: from passive resistance to active destruction.
Sahin-Tóth M
Protein Pept Lett; 2005 Jul; 12(5):457-64. PubMed ID: 16029158
[TBL] [Abstract][Full Text] [Related]
10. Zymogen activation confers thermodynamic stability on a key peptide bond and protects human cationic trypsin from degradation.
Szabó A; Radisky ES; Sahin-Tóth M
J Biol Chem; 2014 Feb; 289(8):4753-61. PubMed ID: 24403079
[TBL] [Abstract][Full Text] [Related]
11. Pathogenic cellular role of the p.L104P human cationic trypsinogen variant in chronic pancreatitis.
Balázs A; Hegyi P; Sahin-Tóth M
Am J Physiol Gastrointest Liver Physiol; 2016 Apr; 310(7):G477-86. PubMed ID: 26822915
[TBL] [Abstract][Full Text] [Related]
12. Defective binding of SPINK1 variants is an uncommon mechanism for impaired trypsin inhibition in chronic pancreatitis.
Szabó A; Toldi V; Gazda LD; Demcsák A; Tőzsér J; Sahin-Tóth M
J Biol Chem; 2021; 296():100343. PubMed ID: 33515547
[TBL] [Abstract][Full Text] [Related]
13. Disulfide engineering of human Kunitz-type serine protease inhibitors enhances proteolytic stability and target affinity toward mesotrypsin.
Cohen I; Coban M; Shahar A; Sankaran B; Hockla A; Lacham S; Caulfield TR; Radisky ES; Papo N
J Biol Chem; 2019 Mar; 294(13):5105-5120. PubMed ID: 30700553
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive functional analysis of chymotrypsin C (CTRC) variants reveals distinct loss-of-function mechanisms associated with pancreatitis risk.
Beer S; Zhou J; Szabó A; Keiles S; Chandak GR; Witt H; Sahin-Tóth M
Gut; 2013 Nov; 62(11):1616-24. PubMed ID: 22942235
[TBL] [Abstract][Full Text] [Related]
15. Presence versus absence of hydrogen bond donor Tyr-39 influences interactions of cationic trypsin and mesotrypsin with protein protease inhibitors.
Salameh MA; Soares AS; Alloy A; Radisky ES
Protein Sci; 2012 Aug; 21(8):1103-12. PubMed ID: 22610453
[TBL] [Abstract][Full Text] [Related]
16. Chymotrypsin C (caldecrin) promotes degradation of human cationic trypsin: identity with Rinderknecht's enzyme Y.
Szmola R; Sahin-Tóth M
Proc Natl Acad Sci U S A; 2007 Jul; 104(27):11227-32. PubMed ID: 17592142
[TBL] [Abstract][Full Text] [Related]
17. Binding of the bovine pancreatic secretory trypsin inhibitor (Kazal) to bovine serine (pro)enzymes.
Menegatti E; Guarneri M; Bolognesi M; Ascenzi P; Amiconi G
J Mol Biol; 1987 Nov; 198(1):129-32. PubMed ID: 3430603
[TBL] [Abstract][Full Text] [Related]
18. Sequence and conformational specificity in substrate recognition: several human Kunitz protease inhibitor domains are specific substrates of mesotrypsin.
Pendlebury D; Wang R; Henin RD; Hockla A; Soares AS; Madden BJ; Kazanov MD; Radisky ES
J Biol Chem; 2014 Nov; 289(47):32783-97. PubMed ID: 25301953
[TBL] [Abstract][Full Text] [Related]
19. Determinants of chymotrypsin C cleavage specificity in the calcium-binding loop of human cationic trypsinogen.
Szabó A; Sahin-Tóth M
FEBS J; 2012 Dec; 279(23):4283-92. PubMed ID: 23035638
[TBL] [Abstract][Full Text] [Related]
20. Interaction between serine (pro)enzymes, and Kazal and Kunitz inhibitors.
Antonini E; Ascenzi P; Bolognesi M; Gatti G; Guarneri M; Menegatti E
J Mol Biol; 1983 Apr; 165(3):543-58. PubMed ID: 6188849
[No Abstract] [Full Text] [Related]
[Next] [New Search]
